Molecure S.A. Logo

Molecure S.A.

Develops first-in-class small molecule drugs for oncology and inflammatory/fibrotic diseases.

MOC | WAR

Overview

Corporate Details

ISIN(s):
PLONCTH00011
LEI:
2594003L11V38ZCVKZ09
Country:
Poland
Address:
Warszawa Żwirki i Wigury 101, 02-089 Warszawa
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Molecure S.A. is a clinical-stage biotechnology company that discovers and develops first-in-class small molecule drugs. The company focuses on treating diseases with high unmet medical needs, primarily in oncology and inflammatory and fibrotic conditions. Leveraging its in-house medicinal chemistry and biology capabilities, Molecure targets novel and unexplored protein and mRNA targets through its proprietary discovery platform. Its business model involves advancing a diverse pipeline of drug candidates to the clinical stage before engaging in licensing agreements for late-stage development and commercialization. The company was formerly known as OncoArendi, changing its name in March 2022.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-27 07:11
Quarterly Report
Skonsolidowany raport Grupy Kapitałowej za III kwartał 2025 roku
Polish 2.6 MB
2025-10-22 19:50
Report Publication Announcement
Zmiana terminu publikacji raportu za III kwartał 2025 roku. - Content (PL)
Polish 917 bytes
2025-10-21 16:00
Declaration of Voting Results & Voting Rights Announcements
Wykaz akcjonariuszy posiadających co najmniej 5% liczby głosów na Nadzwyczajnym…
Polish 2.0 KB
2025-10-21 15:46
Post-Annual General Meeting Information
Treść powziętych uchwał
Polish 229.8 KB
2025-10-21 15:46
Post-Annual General Meeting Information
Treść uchwał podjętych przez Nadzwyczajne Walne Zgromadzenie w dniu 21 paździer…
Polish 686 bytes
2025-09-30 07:56
Audit Report / Information
Raport z przeglądu SSF 30.06.2025
Polish 236.4 KB
2025-09-30 07:56
Audit Report / Information
Raport z przeglądu JSF 30.06.2025
Polish 233.4 KB
2025-09-30 07:56
Management Discussion and Analysis
Sprawozdanie Zarządu z działalności Molecure S.A. 30.06.2025
Polish 1.5 MB
2025-09-30 07:56
Interim Report
Skonsolidowane Sprawozdanie Finansowe Molecure S.A. 30.06.2025
Polish 1.1 MB
2025-09-30 07:56
Interim Report
Jednostkowe Sprawozdanie Finansowe Molecure S.A. 30.06.2025
Polish 1.2 MB
2025-09-26 17:16
Regulatory News Service
Informacja o pozytywnej ocenie wniosku Spółki w ramach ścieżki "SMART" - Projek…
Polish 2.5 KB
2025-09-23 15:18
Pre-Annual General Meeting Information
Zaktualizowane projekty uchwał
Polish 225.0 KB
2025-09-23 15:18
Pre-Annual General Meeting Information
Aktualizacja Zarządu dotycząca projektu Uchwały Nadzwyczajnego Walnego Zgromadz…
Polish 4.9 KB
2025-09-22 20:37
Pre-Annual General Meeting Information
Załącznik - Projekty uchwał
Polish 227.6 KB
2025-09-22 20:37
Pre-Annual General Meeting Information
Projekty uchwał Nadzwyczajnego Walnego Zgromadzenia - Content (PL)
Polish 469 bytes

Automate Your Workflow. Get a real-time feed of all Molecure S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Molecure S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Molecure S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Qurient Co., Ltd. Logo
Biopharma developing novel drugs for cancer, inflammation, and infectious diseases.
South Korea
115180
Rafael Holdings, Inc. Logo
Invests in and develops novel therapeutics for cancer and rare diseases.
United States of America
RFL
RaQualia Pharma Inc. Logo
An R&D firm discovering novel small molecules for out-licensing to pharma partners.
Japan
4579
Recruit Holdings Co., Ltd. Logo
Global provider of HR tech (Indeed), staffing services, and business SaaS solutions.
Japan
6098
RELMADA THERAPEUTICS, INC. Logo
A clinical-stage biotech developing novel therapies for CNS diseases and oncology.
United States of America
RLMD
Renascience Inc. Logo
Develops innovative drugs and AI-powered medical devices for aging and hereditary diseases.
Japan
4889
Rentracks CO.,LTD. Logo
A pay-per-performance ad network with a closed ASP and comprehensive web consulting services.
Japan
6045
Replimune Group, Inc. Logo
Clinical-stage biotech developing oncolytic immunotherapies to treat a broad range of cancers.
United States of America
REPL
ReproCELL Incorporated Logo
Offers stem cell tech, gene editing & drug discovery services for preclinical/clinical research.
Japan
4978
RESEARCH FRONTIERS INC Logo
Develops and licenses smart glass tech for instant light, UV, and heat control.
United States of America
REFR

Talk to a Data Expert

Have a question? We'll get back to you promptly.